PARIS, Nov 5 (APM) - Christopher Viehbacher has resigned as president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), following his dismissal as Sanofi CEO last week, the trade body said on Wednesday.
“It has been announced that Chris Viehbacher is no longer Sanofi CEO. Consequently, Chris has resigned as EFPIA president,” EFPIA said in an email to APM.
Viehbacher will be replaced by Novartis CEO, Joseph Jimenez, acting as interim president until a successor is elected on December 9, EFPIA said.
It was already planned that EFPIA vice-president Jimenez would become president as of June on a standard two-year mandate.
The Sanofi board unanimously decided to sack Viehbacher on October 29, amid suggestions of management problems, poor implementation of strategy and a lack of confidence in him. (APMMA 40268).
Jimenez, aged 54, was appointed CEO of Novartis in February 2010. He began his career within the U.S. company Clorox, before joining H.J. Heinz as head of the group’s activity in North America.
Jimenez has a degree from Stanford University and an MBA from the University of California, Berkeley. He was also non-executive director of AstraZeneca between 2002 and 2007 and an adviser for the Blackstone venture-capital fund.
He joined Novartis in April 2007 as head of the Consumer Healthcare Division, before being appointed head of the pharmaceuticals division in October that year.
gb/aki/ns
TRY APM Market Access AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
Our coverage includes:
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
REQUEST
an initial 10 day temporary access of APM Market Access.
